Chemical formula: C₂₄H₂₅FN₆O Molecular mass: 432.503 g/mol PubChem compound: 65906
Mizolastine interacts in the following cases:
Concurrent use of other potent inhibitors or substrates of hepatic oxidation (cytochrome P450 3A4) with mizolastine should be approached with caution. These would include cimetidine, ciclosporin, and nifedipine.
The safety of mizolastine for use in human pregnancy has not been established. The evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to the development of the embryo or foetus, the course of gestation and peri- and post-natal development. However, as with all medicinal products, mizolastine should be avoided in pregnancy, particularly during the first trimester.
Mizolastine is excreted into breast milk, therefore its use by lactating women is not recommended.
Most patients taking mizolastine may drive or perform tasks requiring concentration. However, in order to identify sensitive people who have unusual reactions to medicinal products, it is advisable to check the individual response before driving or performing complicated tasks.
Common: dry mouth, diarrhoea, abdominal pain (including dyspepsia), nausea.
Not known: vomiting.
Common: drowsiness often transient, headache, dizziness.
Uncommon: anxiety and depression.
Uncommon: raised liver enzymes.
Very rare: low neutrophil count.
Common: asthenia often transient, increased appetite associated with weight gain.
Very rare: allergic reactions including anaphylaxis, angioedema, generalized rash/urticaria, pruritus and hypotension.
Uncommon: hypotension, tachycardia, palpitations.
Very rare: vasovagal attack.
Uncommon: arthralgia and myalgia.
There were reports of bronchospasm and aggravation of asthma but in view of the high frequency of asthma in the patient population being treated, a causal relationship remains uncertain.
Treatment with certain antihistamines has been associated with QT interval prolongation increasing the risk of serious cardiac arrhythmias in susceptible subjects.
Minor changes in blood sugar and electrolytes have been observed rarely. The clinical significance of these changes in otherwise healthy individuals remains unclear. Patients at risk (diabetics, those susceptible to electrolyte imbalance and cardiac arrhythmias) should be monitored periodically.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
